First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

PURPOSE. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Díaz-Rubio, Eduardo, Gómez-España, Auxiliadora, Massutí, Bartomeu, Sastre, Javier, Abad, Albert, Valladares, Manuel, Rivera, Fernando, Safont, Maria J., Martínez de Prado, Purificación, Gallén, Manuel, González, Encarnación, Marcuello, Eugenio, Benavides, Manuel, Fernández-Martos, Carlos, Losa, Ferrán, Escudero, Pilar, Arrivi, Antonio, Cervantes, Andrés, Dueñas, Rosario, López-Ladrón, Amelia, Lacasta, Adelaida, Llanos, Marta, Tabernero, Jose M., Antón, Antonio, Aranda, Enrique
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2012
Teme:
Academia-Pharma Intersect
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267817/
https://ncbi.nlm.nih.gov/pubmed/22234633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0249
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items